Barclays PLC Reduces Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Barclays PLC reduced its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 11.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 41,976 shares of the medical research company's stock after selling 5,406 shares during the quarter. Barclays PLC owned approximately 0.15% of Bio-Rad Laboratories worth $14,043,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Van ECK Associates Corp increased its stake in shares of Bio-Rad Laboratories by 97.8% in the third quarter. Van ECK Associates Corp now owns 1,303,752 shares of the medical research company's stock worth $436,861,000 after purchasing an additional 644,530 shares in the last quarter. Select Equity Group L.P. increased its stake in Bio-Rad Laboratories by 26.2% in the 2nd quarter. Select Equity Group L.P. now owns 649,522 shares of the medical research company's stock worth $177,391,000 after buying an additional 134,856 shares in the last quarter. First Eagle Investment Management LLC raised its holdings in Bio-Rad Laboratories by 32,296.9% during the second quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company's stock valued at $173,773,000 after acquiring an additional 634,311 shares during the period. Earnest Partners LLC lifted its position in shares of Bio-Rad Laboratories by 17.8% in the second quarter. Earnest Partners LLC now owns 606,788 shares of the medical research company's stock valued at $165,720,000 after acquiring an additional 91,882 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Bio-Rad Laboratories by 64.4% in the second quarter. Dimensional Fund Advisors LP now owns 494,604 shares of the medical research company's stock worth $135,081,000 after acquiring an additional 193,700 shares during the period. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on BIO. StockNews.com raised Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a report on Friday, November 1st. Citigroup upped their target price on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Wells Fargo & Company assumed coverage on shares of Bio-Rad Laboratories in a report on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 price target on the stock. Finally, Royal Bank of Canada raised their price objective on Bio-Rad Laboratories from $369.00 to $481.00 and gave the company an "outperform" rating in a research report on Monday, December 9th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, Bio-Rad Laboratories has an average rating of "Moderate Buy" and a consensus price target of $394.20.

Bio-Rad Laboratories Price Performance

Bio-Rad Laboratories stock traded up $6.91 during mid-day trading on Monday, reaching $343.19. 221,117 shares of the company's stock traded hands, compared to its average volume of 241,495. Bio-Rad Laboratories, Inc. has a 12-month low of $262.12 and a 12-month high of $387.99. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16. The stock has a 50 day moving average of $341.40 and a two-hundred day moving average of $321.72. The company has a market cap of $9.61 billion, a price-to-earnings ratio of -12.56 and a beta of 0.90.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.85. The firm had revenue of $649.70 million for the quarter, compared to analysts' expectations of $628.18 million. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The business's revenue was up 2.8% compared to the same quarter last year. During the same period in the prior year, the company earned $2.33 EPS. Equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.29 earnings per share for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.